{"a":[{"_":"Akeso CEO looks beyond lung cancer with biliary tract win, counters ivonescimab debate","$":{"href":"/pharma/akeso-ceo-looks-beyond-lung-cancer-phase-3-biliary-tract-win-counters-ivonescimab-debate","hreflang":"en"}}]}

Phase 3positiveivonescimabPositive

AI Analysis

Summary

Akeso announced a phase 3 win for ivonescimab in biliary tract cancer, with CEO Michelle Xia highlighting the PD-1xVEGF bispecific antibody's potential beyond its non-small cell lung cancer indication despite ongoing debate regarding the drug's data.

Clinical Trial Data

Phase

Primary Endpoint

Met

Outcome Details

Phase 3 win in biliary tract cancer

Importance:7/10

Sentiment:

0.60

Phase 3 dataBiliary tract cancerPD-1xVEGF bispecific antibodyOncology

Read the original article

Published by FierceBiotech on August 26, 2026 10:48 AM

Read Original